BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31255259)

  • 21. Meeting the challenges of interpreting variants of unknown clinical significance in BRCA testing.
    Lattimore V; Currie M; Lintott C; Sullivan J; Robinson BA; Walker LC
    N Z Med J; 2015 Aug; 128(1419):56-61. PubMed ID: 26365847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age at diagnosis may trump family history in driving BRCA testing in a population of breast cancer patients.
    Vig HS; McCarthy AM; Liao K; Demeter MB; Fredericks T; Armstrong K
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1778-85. PubMed ID: 23917453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Missed opportunities in the real-world genetic testing in BRCA gene variant carriers with cancers meeting NCCN criteria.
    Lee SS; Rajeev P; Finning S; Oh C; Pothuri B
    Gynecol Oncol; 2023 Mar; 170():32-37. PubMed ID: 36610379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
    Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
    Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
    Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
    Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
    Bayraktar S; Elsayegh N; Gutierrez Barrera AM; Lin H; Kuerer H; Tasbas T; Muse KI; Ready K; Litton J; Meric-Bernstam F; Hortobagyi GN; Albarracin CT; Arun B
    Cancer; 2012 Mar; 118(6):1515-22. PubMed ID: 22009639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
    Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of BRCA Mutation Test in the U.S., 2004-2014.
    Guo F; Hirth JM; Lin YL; Richardson G; Levine L; Berenson AB; Kuo YF
    Am J Prev Med; 2017 Jun; 52(6):702-709. PubMed ID: 28342662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
    Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic testing and interpretive complexity: a BRCA1 gene mutation example.
    Gogarty DS; Farrell MP; Gallagher DJ
    Ir J Med Sci; 2016 Nov; 185(4):955-957. PubMed ID: 25503966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.
    Negri S; De Ponti E; Sina FP; Sala E; Dell'Oro C; Roversi G; Lazzarin S; Delle Marchette M; Inzoli A; Toso C; Fumagalli S; Campanella M; Kotsopoulos J; Fruscio R
    Mol Genet Genomic Med; 2022 Dec; 10(12):e2071. PubMed ID: 36307994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18-64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas - United States, 2009-2014.
    Kolor K; Chen Z; Grosse SD; Rodriguez JL; Green RF; Dotson WD; Bowen MS; Lynch JA; Khoury MJ
    MMWR Surveill Summ; 2017 Sep; 66(15):1-11. PubMed ID: 28880857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
    Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL
    J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic testing in a cohort of young patients with HER2-amplified breast cancer.
    Eccles DM; Li N; Handwerker R; Maishman T; Copson ER; Durcan LT; Gerty SM; Jones L; Evans DG; Haywood L; Campbell I
    Ann Oncol; 2016 Mar; 27(3):467-73. PubMed ID: 26681682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer genetic testing: NCCN familial high-risk assessment: breast/ovarian.
    Daly MB
    Can J Urol; 2019 Oct; 26(5 Suppl 2):29-30. PubMed ID: 31629424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disparities in BRCA testing: when insurance coverage is not a barrier.
    Olaya W; Esquivel P; Wong JH; Morgan JW; Freeberg A; Roy-Chowdhury S; Lum SS
    Am J Surg; 2009 Oct; 198(4):562-5. PubMed ID: 19800469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence to National Comprehensive Cancer Network Guidelines for
    Bobbili P; Olufade T; DerSarkissian M; Shenolikar R; Yu H; Duh MS; Tung N
    Hered Cancer Clin Pract; 2020; 18():13. PubMed ID: 32518611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.